Incyte Corporation  

(Public, NASDAQ:INCY)   Watch this stock  
Find more results for Incyte Corporation�
+0.88 (2.04%)
Apr 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 42.74 - 44.70
52 week 18.23 - 70.86
Open 43.31
Vol / Avg. 3.15M/2.42M
Mkt cap 7.28B
P/E     -
Div/yield     -
EPS -0.53
Shares 165.54M
Beta 1.45
Inst. own 100%
May 1, 2014
Q1 2014 Incyte Corporation Earnings Release - 7:00AM EDT - Add to calendar
Mar 11, 2014
Incyte Corporation at Barclays Healthcare Conference - Webcast
Mar 3, 2014
Incyte Corporation at Cowen Health Care Conference - Webcast
Feb 12, 2014
Q4 2013 Incyte Corporation Earnings Conference Call - Webcast
Feb 12, 2014
Q4 2013 Incyte Corporation Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -44.16% -23.43%
Operating margin -16.63% -4.54%
EBITD margin - 3.69%
Return on average assets -34.85% -17.32%
Return on average equity - -
Employees 481 -
CDP Score - -


United States - Map
+1-302-4986700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. The Company�s compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received worldwide development and commercialization rights for the compound for inflammatory and autoimmune diseases. The JAK family is composed of four tyrosine kinases JAK1, JAK2, JAK3 and Tyk2 that are involved in the signaling of a number of cytokines and growth factors.

Officers and directors

Richard U. De Schutter Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Herve Hoppenot President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
David C. Hastings Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Eric H. Siegel Executive Vice President, General Counsel
Age: 48
Bio & Compensation  - Reuters
Paula J. Swain Executive Vice President - Human Resources
Age: 55
Bio & Compensation  - Reuters
James M. Daly Executive Vice President, Chief Commercial Officer
Age: 51
Bio & Compensation  - Reuters
Richard S. Levy M.D. Executive Vice President, Chief Drug Development and Medical Officer
Age: 55
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Director
Age: 70
Bio & Compensation  - Reuters
Roy A. Whitfield Director
Age: 59
Bio & Compensation  - Reuters
Barry Michael Ariko Independent Director
Age: 65
Bio & Compensation  - Reuters